MAPT and Alzheimer disease: This study demonstrated that enhancing sleep quality in AD patients significantly lowers their blood levels of Aβ42/40 and Tau-pT181 biomarkers while also improving neuropsychological outcomes and reducing depression and anxiety symptoms [160].